Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the ...

Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10x Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the ...

Ladies and gentlemen, thank you so much for standing by and welcome to 10x Genomics First Quarter 2025 Earnings Conference Call. Please note that this call is being recorded. After speakers ...

Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock ...

While Pacific Biosciences' earnings were beat, shrinking sales, high debt, and poor macro environment do not inspire ...

Results continue to indicate high-grade mineralization and the long-term potential of the deposit (All amounts expressed in U ...